Latest Ibritumomab tiuxetan Stories
SAN DIEGO, Oct. 21, 2008 (GLOBE NEWSWIRE) -- Tracon Pharmaceuticals, Inc., a biopharmaceutical company developing targeted therapies for cancer and eye diseases, today announced the appointment of Bryan Leigh, M.D. as Chief Medical Officer. Dr.
SEATTLE, Oct. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
Genentech and Biogen Idec have announced that a global Phase III study of Rituxan in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival, as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia compared to chemotherapy alone.
Cell Therapeutics, a biopharmaceutical company, has submitted a supplemental biologics license application to the FDA for use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma.
SEATTLE, Oct. 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a supplemental Biologics License Application (sBLA) with the U.S.
By DeNardo, Gerald Advances in imaging technology have made it possible to view molecular pathways within living individuals as never before.
Cell Therapeutics has announced that following a meeting with the FDA data from the first-line indolent trial would be sufficient to support a submission for a supplemental biologics license application.
SEATTLE, Sept. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced today that following a meeting with the U.S.
InNexus Biotechnology, a drug development company, has announced the results of an extensive mouse tumor study demonstrating superiority of the company's DXL625 compared to Rituxan in the xenograft model.
- In medieval musical notation, a sign or neume denoting a shake or trill.